- Ideas
- Markets
- Cryptocurrencies
- Currencies
- Stocks
- Earnings Calendar
- Stock Screener
- Large-Cap
- Top Gainers
- Top Losers
- Most Active
- Most Volatile
- Overbought
- Oversold
- All Time High
- All Time Low
- Sector & Industry
Apple, Advanced Micro Devices Inc, Amazon Com Inc, TESLA INC, NETFLIX INC, Facebook Inc
- Indices
S&P 500, Nasdaq Composite, Dow 30, Nikkei 225, DAX Index, FTSE 100
- Futures
- Bonds
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
- CFDs
Gold, Brent Oil, Crude Oil, CFDs on Natural Gas, Palladium, Silver
- Scripts
- Oscillators
- Centered Oscillators
- Volatility
- Trend Analysis
- Volume
- Moving Average
- Exponential Moving Average (EMA)
- Weighted Moving Average (WMA)
- Simple Moving Average (SMA)
- Hull Moving Average (HMA)
- Kaufman's Adaptive Moving Average (KAMA)
- Smoothed Moving Average (SMMA)
- Variable Index Dynamic Average (VIDYA)
- Volume-weighted Moving Average (VWMA)
- Fractal Adaptive Moving Average (FRAMA)
- Double Exponential Moving Average (DEMA)
- Breadth Indicators
- Bill Williams Indicators
- Screener
- Streams
- Brokers
- Chart
- More
GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10
NASDAQ
GRFS
GRFS
GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10
Prev
Open
Volume
—
Day's Range
Prev
Open
Volume
—
Day's Range
GRFS, D
Long
GRFS: Grifols 2019-02-07 12:31:00 Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System
1
GRFS, 30
Long
GRFS: Grifols 2018-08-16 08:00:00 Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins
1
Valuation
Enterprise Value/EBITDA, TTM
—
Enterprise Value, FQ
—
Market Cap — Basic
—
Number of Employees
—
Number of Shareholders
—
Price/Earnings, TTM
—
Price/Revenue, TTM
—
Price/Book Ratio, FY
—
Price/Sales Ratio, FY
—
Balance Sheet
Current Ratio, FQ
—
Debt to Equity, FQ
—
Net Debt, FQ
—
Quick Ratio, FQ
—
Total Assets, FQ
—
Total Debt, FQ
—
Operating Metrics
Return on Assets, TTM
—
Return on Equity, TTM
—
Return on Invested Capital, TTM
—
Revenue per Employee, TTM
—
Price History
Average Volume (10 day)
—
Beta - 1 Year
—
Price - 52 Week High
—
Price - 52 Week Low
—
Dividends
Dividends Paid, FY
—
Dividends per Share, FY
—
Expected Annual Dividends
—
Dividends Yield
—
Margins
Net Margin, TTM
—
Gross Margin, TTM
—
Operating Margin, TTM
—
Pretax Margin, TTM
—
Income Statement
Basic EPS, Net Income
—
Earnings per Share, Basic, TTM
—
EBITDA, TTM
—
Gross Profit, FY
—
Last Annual EPS
—
Last Annual Revenue, FY
—
Net Income, FY
—
Total Revenue, FY
—
Free Cash Flow, TTM
—
Sector: Health Technology
Industry: Pharmaceuticals: Major
Employees: 21243
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
News
Community & Tools
For Business
© 2020 TradingView.
Made with
Select market data provided by ICE Data Services